Replies to post #98376 on Cytodyn Inc (CYDY)

[Emergcy]

Thanks Smiley.
This German study,explained by Dr. Been, is another excellent prove of the solution for COVID: leronlimab.

[Amatuer17]

This was a very good session - listen from 18 minutes onwards

The conclusion and how CCR5 binding can control the disease - that is direct connection to why Lero is working.

Someone should forward this to Dr BP and NP.

Side question - any drugs for interferon control? That is real control for critical patients.

[CI Ventures]

Here’s some CCR1 drugs that could combine with Leronlimab if the study is accurate.

https://www.eurekaselect.com/86440/article/ccr1-antagonists-what-have-we-learned-clinical-trials

The identification of chemokines and their receptors as potent mediators of leukocyte infiltration raised interest in the potential role of these proteins on disease pathogenesis. This is exemplified by the chemokine receptor, CCR1, which has been shown to be up-regulated in a number of human diseases, the implications of which have been suggested by animal models where inhibition of CCR1 or its ligands have shown beneficial effects. These data support the possibility that a CCR1 antagonist will provide therapeutic benefit to patients with inflammatory diseases. Over the last several years, several of these antagonists entered clinical trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD. This review will describe the evidence that supported the role of CCR1 in these diseases, the results from clinical trials, and provide perspectives on what has been learned from these trials for potential application / consideration to other studies with chemokine receptor antagonists.

[DaltonDog]

Smiley This video by Dr. Been is very interesting in respects to M2M vs S/C. What some people said on this and other boards is that Lero would work better in S/C than M2M, but this video is say it will keep people from progressing. Which is what the safety data implied, fewer patients with SAEs means fewer progressed.He says as the macrophages enter the lungs they express CCR1 and CCR5, which happens at the transition from moderate to severe. So Lero should work well in both phases, but may be better to keep people from progressing to severe.